Retatrutide (GLP 3-RT)

Retatrutide (often dubbed “GLP-3” or “triple-G”) is an investigational, once-weekly injectable drug developed by Eli Lilly that targets three receptors—GLP-1, GIP, and glucagon—to promote significant weight loss. Phase 2 and 3 studies have shown it may result in up to 25%–28.7% weight loss, targeting obesity, type 2 diabetes, and potentially fatty liver disease, with phase 3 trials expected to be completed in mid-2026.

CN: LY-3437943

FOR RESEARCH USE ONLY